Pro Medicus shares (ASX: PME) continue to put up a strong recovery this week, climbing 8.28% to A$132.08 on the day, and extending gains to 15.45% over the past five trading sessions. The move is not solely linked to the broader market bump, as a contract for five-years, at A$23 million was announced with the University of Maryland Medical System.
The contract announcement provided a much-needed catalyst for Pro Medicus shares, which remain down 40.67% year-to-date despite the recent bounce. The stock had suffered through a prolonged derating through the second half of 2025, with the 52 week high of A$336 a long way away. Today’s news however has been a boost for PME bulls, with the market interpreting the UMMS deal as validation that the company’s fundamental growth trajectory remains intact despite the share price carnage.
Contract News A Boost
The University of Maryland Medical System agreement will see Pro Medicus deploy its Visage 7 Viewer and Visage 7 Workflow solutions across UMMS’s extensive network, which includes major hospitals and trauma centres throughout Maryland. Implementation is scheduled to begin immediately, with full rollout and go-live targeted for early 2027. The contract structure follows Pro Medicus’s proven transaction-based licensing model, where revenue is tied to the volume of imaging studies processed through the platform. This arrangement creates potential for the deal to exceed its A$23 million minimum value if scan volumes increase over the five-year term, a pattern that has historically played out in the company’s favour at existing client sites.
The UMMS win extends Pro Medicus’s footprint in the strategically important Mid-Atlantic region, complementing its existing presence with MedStar Health and other Maryland-based healthcare systems. The cloud-based deployment represents a shift away from legacy on-premises picture archiving and communication systems, positioning Pro Medicus as a beneficiary of the broader industry migration toward cloud-native imaging infrastructure.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The UMMS announcement comes on the heels of a strong run of contract wins and renewals that have bolstered confidence in Pro Medicus’s competitive positioning. In March, the company secured A$40 million in US contract renewals, including a A$31 million five-year extension with MedStar Health and a A$9 million renewal with radiology group Zwanger-Pesiri. Notably, both renewals were signed at higher per-transaction fees than the original agreements, demonstrating pricing power in a market where software vendors often face pressure to discount.
The MedStar renewal also expanded beyond radiology to include Visage 7 Cardiology, marking an important step in Pro Medicus’s strategy to broaden its total addressable market within existing client organisations. Earlier in the year, the company announced three additional US contracts worth A$29 million with Children’s of Alabama, Roswell Park Comprehensive Cancer Center, and Vancouver Clinic.
Pro Medicus reported half-year results to 31 December 2025 that underscored the strength of its underlying business model. Revenue reached A$124.8 million, up approximately 28% year-on-year, while underlying net profit after tax climbed roughly 30% to A$90.7 million. The company continues to generate return on equity above 50%, a rarity among software companies of any size, reflecting its capital-light business model and high gross margins.
Capital Allocation and Buyback Signal
Following the half-year results, Pro Medicus announced an on-market share buyback of up to 10.4 million shares, representing approximately 10% of issued capital. The buyback was widely interpreted as a strong signal from management that the current share price materially undervalues the company’s long-term prospects. With a robust balance sheet carrying substantial net cash and no debt, Pro Medicus has the financial flexibility to return capital to shareholders while continuing to invest in product development and support its expanding client base.
The decision to pursue a sizeable buyback rather than pursue acquisitions or other growth initiatives sparked debate among market watchers. Supporters view it as disciplined capital allocation that will accrete earnings per share if growth continues at historical rates. Sceptics question whether it signals a lack of high-return reinvestment opportunities, though management has consistently highlighted a strong pipeline spanning all market segments.
What Next For PME
Looking ahead, Pro Medicus appears well-positioned to benefit from several secular tailwinds in healthcare IT. The ongoing migration from legacy on-premises systems to cloud-based platforms remains in early innings, with many large health systems yet to complete their transitions. The company’s expanding product suite, including cardiology and other specialty imaging modules, creates opportunities to deepen relationships with existing clients and increase revenue per customer.
Management commentary around a strong pipeline across all market segments suggests the contract flow that has characterised the past several years should continue, though the market has become conditioned to expect a steady cadence of sizable deals. Any extended period without major announcements could test investor patience and trigger renewed volatility.
The integration of artificial intelligence capabilities into medical imaging workflows represents a longer-term opportunity that Pro Medicus is exploring, though commercial applications remain nascent. As radiologists and other specialists seek tools to improve efficiency and diagnostic accuracy, Pro Medicus’s position as the underlying imaging platform could provide a strategic advantage in partnering with or acquiring AI-focused companies.
Bull Case:
- Transaction-based model delivers upside as imaging volumes grow at existing clients
- Strong pricing power demonstrated through renewals at higher per-transaction fees
- Cloud migration tailwind remains multi-year opportunity with large addressable market
- Capital-light model generates exceptional returns and supports aggressive buyback
- Tier-1 reference clients create competitive moat and accelerate new sales
Bear Case:
- Valuation remains elevated despite correction, leaving limited room for execution missteps
- Revenue concentration in North America creates exposure to US healthcare policy risk
- High market expectations require sustained contract flow to avoid disappointment
- Implementation delays on large rollouts could impact revenue recognition timing
- Competition intensifying as legacy vendors invest in cloud-native imaging platforms
Pro Medicus shares are putting up a fight in recent weeks, with the move off $115 now looking to have entrenched the level as a solid line of support. The UMMS contract and recent renewals provide fresh impetus that will have bulls looking to take out some resistance levels and chart a course for earlier heights, however the stock’s still-elevated valuation multiples mean further momentum will be essential to justify a move higher.
